Iwate Medical University Technology: MRI Contrast Agent Containing Monosaccharides: IM19-002
Enables high-sensitivity detection of cancer and extension of imaging time.
The diagnosis of cancer utilizes PET (positron emission tomography), X-ray CT (computed tomography), PET-CT, MRI (Magnetic Resonance Imaging), and other methods. However, there are issues with PET and CT due to high radiation exposure and the low spatial resolution of PET. On the other hand, while MRI does not involve radiation exposure, there is a challenge with the contrast agents used, which are not easily taken up by cancer cells. To address these issues, the present invention provides an MRI contrast agent composition consisting of monosaccharides and MRI contrast agents. This invention allows MRI contrast agents to be more easily absorbed by cancer cells and tissues, significantly improving the contrast effect for cancer, enabling examinations and research with clearer images, as well as magnetic hyperthermia and other applications.
- Company：Tohoku Techno Arch Co., Ltd.
- Price：Other
